Format

Send to

Choose Destination
Nat Rev Microbiol. 2006 Dec;4(12):932-42. Epub 2006 Nov 6.

Group B Streptococcus: global incidence and vaccine development.

Author information

1
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India. akjohri14@yahoo.com

Abstract

An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.

PMID:
17088932
PMCID:
PMC2742968
DOI:
10.1038/nrmicro1552
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center